Groundbreaking IPF Research To Receive Major Grant From NIH

Groundbreaking IPF Research To Receive Major Grant From NIH

An influx of research at the University of Colorado, Denver (UCD) concerning the use of Parion Science’s mucolytic agents to treat idiopathic pulmonary fibrosis (IPF), will be made possible by a $7.9 million-total grant from the National Institutes of Health (NIH). According to a press release from…

Ofev Now FDA-approved for Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) patients received two pieces of good news just recently when the US Food and Drug Administration announced that it has granted approval for two IPF treatments: Esbriet® (pirfenidone) from InterMune, Inc., and Ofev…

Esbriet Now FDA-Approved for Idiopathic Pulmonary Fibrosis

Earlier this month, a second province in Canada finally approved novel pulmonary fibrosis drug Esbriet (pirfenidone) for public funding, which is a giant leap towards improving the lives of thousands of individuals living with idiopathic pulmonary fibrosis…

IPF Drug Esbriet Now Publicly Funded in Canadian Province

New Brunswick, Canada residents currently in the fight against a rare and mysterious disease, idiopathic pulmonary fibrosis (IPF), have received new hope after it was announced that the provincial government has added Esbriet (pirfenidone) to the list of treatments publicly funded under the New Brunswick Prescription Drug…

Mesothelioma Victims Center to Assess Victims for IPF

Asbestos exposure has traditionally been linked to Mesothelioma. Now, however, IPF is also being associated with exposure to asbestos in some cases as well. Mesothelioma, a rare type of cancer that affects the protective lining of internal organs, is a common consequence of asbestos exposure. It can…

Pacific Therapeutics is Testing a Reformulated Pulmonary Fibrosis Drug

Specialty pharmaceutical company Pacific Therapeutics Ltd., known for their strategy on reformulating and improving pre existing FDA-approved drugs, has several leading pipeline products and ongoing research programs targeted at $1 billion dollar markets for erectile dysfunction and pulmonary fibrosis. Recently,…

Novare Pharmaceuticals Launched to Specialize in RHAMM Modulation

Emerging product development and commercialization company Allied Minds has just launched a divisional biopharmaceutical company that will specialize in the utilization of a protein called, RHAMM or Receptor for Hyaluronan Mediated Motility, for the creation of products indicated to enhance the body’s natural reparative mechanisms. The company, Novare Pharmaceuticals, is aiming…

Lung Injury from Carbon Nanotubes Reduced With Aluminum Coating

Although multi walled carbon nanotubes (CNTs) are all the rage in product development, finding applications in sporting goods, electronic devices, and many other products, they pose a potential health hazard similar to asbestos. However, Dr. James Bonner, a professor at North Carolina State University, found a way to reduce…

Pulmonary Fibrosis Case Suggests PF Patients Should Be Screened For Autoimmune Diseases

A case study of pulmonary fibrosis (PF) in association with autoimmune diseases, entitled “A case of pulmonary fibrosis associated with rheumatoid arthritis, scleroderma sine scleroderma and ANCA associated vasculitis” was published in SpringerPlus by Dr. Amritpal Singh Anand from Lakeland Rheumatology and colleagues in Michigan describing a rare…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums